Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Selection of the right cancer treatment is still a challenge. Here, the authors introduce a framework to analyze treatment benefits, using the idea that patients with similar genetic tumor profiles receiving different treatments can be used to model their responses to the alternative treatment.
Enregistré dans:
Auteurs principaux: | Joske Ubels, Pieter Sonneveld, Erik H. van Beers, Annemiek Broijl, Martin H. van Vliet, Jeroen de Ridder |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/bc84203d4d9b4efaa0dbb9de2ebf654a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
par: Mirian Brink, et autres
Publié: (2021) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
par: Liu YC, et autres
Publié: (2014) -
The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma
par: Georgia Stewart, et autres
Publié: (2021) -
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
par: Meletios A. Dimopoulos, et autres
Publié: (2021) -
Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
par: Fatih M. Uckun, et autres
Publié: (2021)